Elliott Investment Management has taken a sizable stake in Bio-Rad Laboratories, an activist move aimed at lifting the life-science company's underperforming share price. The Wall Street Journal reported the position, citing people familiar with the matter. Such bets from prominent activist firms often precede pressure on management to deliver better returns for shareholders.

Bio-Rad Laboratories has seen its stock lag in recent trading, drawing the attention of hands that specialize in unlocking value from neglected names. Elliott's involvement typically signals expectations of changes at the board level or in corporate strategy. The move puts the company squarely on the radar of investors tracking activist campaigns in the healthcare sector.

Activist investors like Elliott tend to move quickly once a position is established, whether through private negotiations or public shareholder activism. For Bio-Rad shareholders, the presence of a known activist on the cap table reshapes expectations around governance and potential operational overhauls.